Format

Send to

Choose Destination
See comment in PubMed Commons below
Health Psychol. 2003 Sep;22(5):541-8.

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.

Author information

  • 1University of Pennsylvania, Dept of Psychiatry, Abramson Cancer Ctr, Philadelphia, PA 19104, USA. clerman@mail.med.upenn.edu

Abstract

This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N=418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 * SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.

PMID:
14570538
DOI:
10.1037/0278-6133.22.5.541
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Psychological Association
    Loading ...
    Support Center